Questcor has been beset by short sellers -- over half its float is sold short -- who cite a myriad of issues from reimbursement pressure for its flagship product Achthar to government inquiries and potential competition from overseas.
Well, scratch one concern off the list. Questcor just struck a deal to acquire Novartis drug Synacthen. Shares popped 15% yesterday and tacked on an additional 7% in gains today.
In this video, health-care analyst David Williamson discusses the deal in further detail and the implications for Questcor investors.
Follow David on Twitter @MotleyDavid.
David Williamson and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Got a Raise? Make the Most of It With These 4 Tips
You could increase the value of your raise many times over.
2 Reasons to Buy Zoe’s Kitchen, 1 Reason to Wait
The fast-casual restaurant chain might be on the verge of a comeback.
Good News: More Than 75% of Americans Are Saving in Some Capacity
Are you one of them?